San Francisco, CA, United States of America

Patrick J McAlary


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Patrick J McAlary

Introduction

Patrick J McAlary is a distinguished inventor based in San Francisco, California. His significant contributions to the field of biotechnology are exemplified by his patent related to the production of interferon-.beta. His work has impacted the way interferon polypeptides are produced, showcasing his expertise and innovative spirit.

Latest Patents

Patrick holds a notable patent titled "Production of interferon-.beta. (IFN-.beta.) in E. coli." This patent outlines methods for producing interferon-.beta. polypeptides using bacterial cells. The patent details a process where cells capable of producing the IFN-.beta. polypeptide are cultured under specific conditions that increase yield. These conditions include low potassium cation concentration, very low sodium cation concentration, and particular pH ranges, demonstrating a thoughtful approach to enhancing production efficiency.

Career Highlights

Currently, Patrick works at Chiron Corporation, a leading biotechnology firm renowned for its research and development in medical therapies. His role involves developing innovative solutions for complex biological challenges, further establishing his reputation in the biotech industry.

Collaborations

Throughout his career, Patrick has collaborated with talented professionals such as Glenn J Dorin and Kathleen M Wong. These partnerships have contributed to furthering research initiatives and have helped advance his projects in biotechnological innovations.

Conclusion

Patrick J McAlary stands out as an influential inventor in the biotechnology sector. His singular patent illustrates his commitment to innovation and the potential of bacterial systems in producing critical therapeutic proteins. With his ongoing work at Chiron Corporation and collaborations with esteemed colleagues, Patrick continues to pave the way for advancements in medical biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…